{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Aldeyra Therapeutics, Inc.
Is Aldeyra Therapeutics, Inc. technically bullish or bearish?
As of June 3, 2025, the trend is mildly bearish, with daily moving averages indicating bearish sentiment, while weekly indicators show mixed signals, leading to a lack of strong momentum overall.
Who are in the management team of Aldeyra Therapeutics, Inc.?
As of March 2022, the management team of Aldeyra Therapeutics, Inc. includes Dr. Richard Douglas (Independent Chairman), Dr. Todd Brady (CEO), and several independent directors: Dr. Ben Bronstein, Mr. Martin Joyce, Ms. Nancy Miller-rich, Dr. Gary Phillips, and Mr. Jesse Treu.
What does Aldeyra Therapeutics, Inc. do?
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for diseases associated with high aldehyde levels. It has a market cap of $185.08 million and reported a net profit loss of $10 million as of March 2025.
How big is Aldeyra Therapeutics, Inc.?
As of Jun 18, Aldeyra Therapeutics, Inc. has a market capitalization of 185.08 million and reported net sales of 0.00 million with a net profit of -57.70 million over the last four quarters. Shareholder's funds were 71.00 million, and total assets were 104.61 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
